线粒体糖尿病的研究进展

摘要

参考文献 (请在框内滑动浏览)

[1] Whittaker RG,Schaefer AM,McFarland R,et al.Prevalence and progression of diabetes in mitochondrial disease[J].Diabetologia,2007,50(10):2085-2089.

[2] Walker M,Taylor RW,Turnbull DM.Mitochondrial diabetes[J].Diabet Med,2005,22(Suppl 4):18-20.

[3] Ohkubo K,Yamano A,Nagashima M,et al.Mitochondrial gene mutations in the tRNA(Leu(UUR)) region and diabetes:prevalence and clinical phenotypes in Japan[J].Clin Chem,2001,47(9):1641-1648.

[4] Maeda K,Kawai H,Sanada M,et al.Clinical Phenotype and Segregation of Mitochondrial 3243A>G Mutation in 2 Pairs of Monozygotic Twins[J].JAMA Neurol,2016,73(8):990-993.

[5] Pickett SJ,Grady JP,Ng YS,et al.Phenotypic heterogeneity in m.3243A>G mitochondrial disease:The role of nuclear factors[J].Ann Clin Transl Neurol,2018,5(3):333-345.

[6] Wang J,Yan D,Cui H,et al.Identification of eight genomic protective alleles for mitochondrial diabetes by Kinship-graph convolutional network[J].J Diabetes Investig,2023,15(1):52-62.

[7] Ishikawa K,Nakada K.Attempts to understand the mechanisms of mitochondrial diseases:The reverse genetics of mouse models for mitochondrial disease[J].Biochim Biophys Acta Gen Subj,2021,1865(3):129835.

[8] Khotina VA,Vinokurov AY,Bagheri Ekta M,et al.Creation of Mitochondrial Disease Models Using Mitochondrial DNA Editing[J].Biomedicines,2023,11(2):532.

[9] 中国医师协会检验医师分会线粒体疾病检验医学专家委员会.线粒体糖尿病临床检验诊断专家共识[J].中华糖尿病杂志,2021,13(9):846-851.

[10]de Laat P,Koene S,van den Heuvel LP,et al.Clinical features and heteroplasmy in blood,urine and saliva in 34 Dutch families carrying the m.3243A>G mutation[J].J Inherit Metab Dis,2012,35(6):1059-1069.

[11]Yang M,Xu L,Xu C,et al.The Mutations and Clinical Variability in Maternally Inherited Diabetes and Deafness:An Analysis of 161 Patients[J].Front Endocrinol (Lausanne),2021,12:728043.

[12]田利华,韩学尧,纪立农.线粒体基因tRNALeu(UUR)A3243G突变糖尿病临床特征的Meta分析[J].中国糖尿病杂志,2018,26(7):543-554.

[13]Shayota BJ.Biomarkers of mitochondrial disorders[J].Neurotherapeutics,2024,21(1):e00325.

[14]Rho EH,Baek SI,Lee H,et al.Clinical Characteristics of Diabetes in People with Mitochondrial DNA 3243A>G Mutation in Korea[J].Diabetes Metab J,2024,48(3):482-486.

[15]Laloi-MichelinM,Meas T,Ambonville C,et al.The clinical variability of maternally inherited diabetes and deafness is associated with the degree of heteroplasmy in blood leukocytes[J].J Clin Endocrinol Metab,2009,94(8):3025-3030.

[16]Yeung RO,Al Jundi M,Gubbi S,et al.Management of mitochondrial diabetes in the era of novel therapies[J].J Diabetes Complications,2021,35(1):107584.

[17]Parikh S,Goldstein A,Koenig MK,et al.Diagnosis and management of mitochondrial disease:a consensus statement from the Mitochondrial Medicine Society[J].Genet Med,2015,17(9):689-701.

[18]Suzuki S,Hinokio Y,Ohtomo M,et al.The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness,and mitochondrial DNA 3243 (A to G) mutation[J].Diabetologia,1998,41(5):584-588.

[19]Janssen MCH,Koene S,de Laat P,et al.The KHENERGY Study:Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders[J].Clin Pharmacol Ther,2019,105(1):101-111.

[20]Johnson SC,Yanos ME,Kayser EB,et al.mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome[J].Science,2013,342(6165):1524-1528.

[21]Di Donfrancesco A,Massaro G,Di Meo I,et al.Gene Therapy for Mitochondrial Diseases:Current Status and Future Perspective[J].Pharmaceutics,2022,14(6):1287.

[22]Gropman AL,Uittenbogaard MN,Chiaramello AE.Challenges and opportunities to bridge translational to clinical research for personalized mitochondrial medicine[J].Neurotherapeutics,2024,21(1):e00311.